These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21859559)

  • 41. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
    Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
    Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.
    Sasaki Y; Hamaguchi T; Arai T; Goto A; Ura T; Muro K; Yamada Y; Shirao K; Shimada Y
    Anticancer Res; 2014 Apr; 34(4):2029-34. PubMed ID: 24692743
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
    Hofheinz RD; Kubicka S; Wollert J; Arnold D; Hochhaus A
    Onkologie; 2006 Dec; 29(12):563-7. PubMed ID: 17202826
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
    Kabbinavar FF; Wallace JF; Holmgren E; Yi J; Cella D; Yost KJ; Hurwitz HI
    Oncologist; 2008 Sep; 13(9):1021-9. PubMed ID: 18776057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.
    Gkioulbasanis I; Souglakos J; Vardakis N; Kotsakis A; Saridaki Z; Kentepozidis N; Polyzos A; Giassas S; Ignatiadis M; Bozionelou V; Christophylakis C; Georgoulias V
    J BUON; 2007; 12(2):197-202. PubMed ID: 17600872
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
    Javle MM; Cao S; Durrani FA; Pendyala L; Lawrence DD; Smith PF; Creaven PJ; Noel DC; Iyer RV; Rustum YM
    Clin Cancer Res; 2007 Feb; 13(3):965-71. PubMed ID: 17289892
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
    Pan CX; Loehrer P; Seitz D; Helft P; Juliar B; Ansari R; Pletcher W; Vinson J; Cheng L; Sweeney C
    Oncology; 2005; 69(1):63-70. PubMed ID: 16088234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multicenter phase II study of CPT-11 fractionated over two days with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer.
    Recchia F; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Di Blasio A; Rea S
    Anticancer Res; 2003; 23(3C):2903-8. PubMed ID: 12926132
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
    Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Lee SS; Lee JS; Kang YK
    Am J Clin Oncol; 2008 Apr; 31(2):151-6. PubMed ID: 18391599
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
    Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH
    Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
    BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Decreasing dosage of irinotecan, 5-flurouracil (5-FU) and leucovorin (LV) in the treatment of advanced and/or metastatic colorectal cancer: a phase II study.
    Huang JS; Yen CL; You YT; Wang CH; Lan YJ; Lai CH; Chueh TC; Liaw CC
    Chang Gung Med J; 2006; 29(3):297-305. PubMed ID: 16924892
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
    Van Cutsem E; Labianca R; Bodoky G; Barone C; Aranda E; Nordlinger B; Topham C; Tabernero J; André T; Sobrero AF; Mini E; Greil R; Di Costanzo F; Collette L; Cisar L; Zhang X; Khayat D; Bokemeyer C; Roth AD; Cunningham D
    J Clin Oncol; 2009 Jul; 27(19):3117-25. PubMed ID: 19451425
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimal use of the combination of irinotecan and 5-fluorouracil.
    Benson AB; Goldberg RM
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):68-77. PubMed ID: 12802797
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current status of capecitabine in the treatment of colorectal cancer.
    Rothenberg ML
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer.
    Alimonti A; Satta F; Pavese I; Burattini E; Zoffoli V; Vecchione A
    Ann Oncol; 2003 May; 14(5):805-6. PubMed ID: 12702539
    [No Abstract]   [Full Text] [Related]  

  • 60. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
    Van Cutsem E; Khayat D; Verslype C; Billemont B; Tejpar S; Meric JB; Soussan-Lazard K; Assadourian S; Cartot-Cotton S; Rixe O
    Eur J Cancer; 2013 Jan; 49(1):17-24. PubMed ID: 22921183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.